http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Jiangtao Lin (검색결과 3 건)
- 무료
- 기관 내 무료
- 유료
-
Jiangtao Lin,Huanying Wan,Jian Kang,Qianli Ma,Ping Chen,Meiling Jin,Haoyan Wang,Shuang Liu,Qinglin Hao,Yong Lin,Lin Su,Na Hu 대한천식알레르기학회 2019 Allergy, Asthma & Immunology Research Vol.11 No.4
Purpose: Asthma affects approximately 30 million patients in China; however, tiotropium data for Chinese patients is limited. This study aimed to assess the efficacy and safety of tiotropium in Chinese patients with moderate symptomatic asthma. Methods: A post hoc subgroup analysis was conducted on 430 Chinese patients pooled from two 24-week, replicate phase 3 trials (NCT01172808 and NCT01172821), in which they received once-daily tiotropium 2.5 μg (Tio R2.5) or 5 μg (Tio R5) (n = 106 or 109, respectively), twice-daily salmeterol 50 μg (Sal 50) (n = 110), or placebo (n = 105), while maintaining inhaled corticosteroids (ICS). The co-primary endpoints assessed in week 24 were forced expiratory volume in 1 second (FEV1) peak0–3h response, trough FEV1 response, and responder rate as assessed using the Asthma Control Questionnaire (ACQ). Results: For both FEV1 peak0–3h responses and trough FEV1 responses, the mean treatment differences were greater for Tio R2.5, Tio R5, and Sal 50 compared with placebo at 0.249 L, 0.234 L, and 0.284 L, and 0.172 L, 0.180 L, and 0.164 L, respectively (P< 0.001). The ACQ responder rate in placebo, Tio R2.5, Tio R5, and Sal 50 was 58.7%, 62.3%, 59.3%, and 69.1%, respectively. Furthermore, 11 (2.6%) of 430 patients had serious adverse events (Tio R5, n = 4; Tio R2.5, n = 1; Sal 50, n = 1; and placebo, n = 5). Conclusions: Once-daily tiotropium, as add-on to medium-dose ICS, was effective and well tolerated for Chinese patients with moderate symptomatic asthma, consistent with the main analysis.
-
Jiangtao Lin,Bin Xing,Huaping Tang,Lan Yang,Yadong Yuan,Yuhai Gu,Ping Chen,Xiaoju Liu,Jie Zhang,Huiguo Liu,Changzheng Wang,Wei Zhou,Dejun Sun,Yiqiang Chen,Zhuochang Chen,Mao Huang,Qichang Lin,Chengpin 대한천식알레르기학회 2020 Allergy, Asthma & Immunology Research Vol.12 No.3
Purpose: Details of patients hospitalized for asthma exacerbation in mainland China are lacking. To improve disease control and reduce economic burden, a large sample survey among this patient population is indispensable. This study aimed to investigate the clinical characteristics and outcomes of such patients. Methods: A retrospective study was conducted on patients hospitalized for asthma exacerbation in 29 hospitals of 29 regions in mainland China during the period 2013 to 2014. Demographic features, pre-admission conditions, exacerbation details, and outcomes were summarized. Risk factors for exacerbation severity were analyzed. Results: There were 3,240 asthmatic patients included in this study (57.7% females, 42.3% males). Only 28.0% used daily controller medications; 1,287 (39.7%) patients were not currently on inhaled corticosteroids. Acute upper airway infection was the most common trigger of exacerbation (42.3%). Patients with severe to life-threatening exacerbation tended to have a longer disease course, a smoking history, and had comorbidities such as hypertension, chronic obstructive pulmonary disease (COPD), and food allergy. The multivariate analysis showed that smoking history, comorbidities of hypertension, COPD, and food allergy were independent risk factors for more severe exacerbation. The number of patients hospitalized for asthma exacerbation varied with seasons, peaking in March and September. Eight patients died during the study period (mortality 0.25%). Conclusions: Despite enhanced education on asthma self-management in China during recent years, few patients were using daily controller medications before the onset of their exacerbation, indicating that more educational efforts and considerations are needed. The findings of this study may improve our understanding of hospital admission for asthma exacerbation in mainland China and provide evidence for decision-making.
-
Jiangtao Su,Na Lin,Xiangyu You,Heshuang Dai,Meng Rao,Lu Ye,Fan Ye,Le Cai,Yuxin Chen,Gao Zhou,Xiaoxia Guo 한국고분자학회 2023 Macromolecular Research Vol.31 No.11
Systemic toxicity, poor aqueous solubility, and poorly cell permeable ability hindered the clinical application of Celastrol. In this study, we aimed to design and synthesize an amphiphilic conjugate to encapsulate Celastrol into micelles to improve its water solubility, cellular membrane penetration, improving the clinic translation potential of Celastrol for the treatment of psoriasis. For this purpose, we first synthesized gelatin and oleic acid conjugate (GOC-1), and then covalently bonded 4-(3-boronophenylamino)-4-oxobutanoic acid (BPOA) with GOC-1 to form a stable GOC-2 conjugate which can self-assemble into micelles in aqueous solution. Celastrol (Cel) was physically encapsulated into the core of GOCs micelles. The dynamic stability, particle size, drug release, zeta potential, drug-loading efficiency, and surface morphology of Cel/loaded GOCs nano-micelles were determined. In addition, cell viability, cellular uptake of Cel/loaded GOC-2, and skin permeation and in vivo anti-psoriasis effect of Cel-loaded GOC-2 were investigated. Our results have shown that Cel/loaded GOC-1 and Cel/loaded GOC-2 have spherical shapes with diameters of around 200–300 nm. Compared to GOC-1, GOC-2 micelles showed higher drug-loading efficiency and excellent permeation ability in vitro. Moreover, Cel/GOC-2 micelles reduced erythema and white scales on the dorsal skin of psoriatic mice. In conclusion, BPOA attached GOC nanoparticles as a Celastrol carrier not only increase its water solubility but also improve drug-loading efficiency and cell permeation ability, exhibiting superior anti-psoriatic effect than the commercially available tacrolimus. Our work is expected to provide a facile approach to prepare nanocarrier for Celastrol to improve the clinic translation potential of Celastrol.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
